Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -9 of 9
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Comparative Trial Between Bexxar and Zevalin
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Approved-not yet active
18 and over
Pharmaceutical / Industry
CCBX001-053
NCT00078676
2.
Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
60 and over
Pharmaceutical / Industry
307940/106-20
NCT00322218
3.
A Study of Two Associations of Rituximab and Chemotherapy, With a PET–Driven Strategy, in Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 59
Other
2007.462
NCT00498043
4.
Safety Study to Evaluate Induction and Consolidation Treatment Combination in Mantle Cell Lymphoma Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 70
Other
GELTAMO-LCM-04-02
NCT00505232
5.
A Study of Zevalin and Simultaneous Application of BEAM High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 65
Other
DSHNHL 2004-R4
DSHNHL 2004-R4, NCT00521560
6.
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-Based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 65
Other
CHUBX 2007/11
NCT00607854
7.
Allogenic Stem Cell Transplantation (SCT) With Non-Myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 65
Other
GELTAMO-Z-RIC-Allo
EuDRACT nº:2007-003302-10, NCT00644371
8.
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Approved-not yet active
18 to 75
Other
ZAR2007
NCT00662948
Last Modified:
11/16/2006
 
First Published:
10/21/2006
9.
Phase I Study of a Conditioning Regimen Comprising High-Dose Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Vinorelbine Ditartrate- and Filgrastim (G-CSF)-Mobilized Autologous Stem Cell Transplantation in Elderly Patients With Relapsed or Refractory CD20-Positive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
65 and over
Other, Pharmaceutical / Industry
SWS-SAKK-37/05
EU-20648, SPRI-SWS-SAKK-37/05, NCT00392691
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute